Please note: This review reflects information we gathered on the date it was researched and may now be out of date. Providers frequently change their pricing, plans, medications, and policies. Any ratings, reviews, and customer feedback are gathered from publicly available online sources and may have since changed or no longer be accurate. Always do your own research and confirm the latest details directly with the provider before making any decision.
Try Ageless Review
It tells you plainly that compounded GLP-1s are not FDA-approved — and then prices itself against a retail figure the manufacturers stopped charging.
Try Ageless
Price The Approved Drug FirstGenuine credit first: the site states repeatedly that “compounded medications, including semaglutide and tirzepatide, are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality”, and warns they may differ from the branded product in formulation, inactive ingredients or device. It names two clinicians, gates TRT behind bloodwork, and includes HCG and enclomiphene for fertility preservation.
The problem is the maths. The page compares against ~$1,300/month retail and ~$15,600 a year, claiming you save ~$13,700. But NovoCare sells Wegovy self-pay at $349/month and LillyDirect sells Zepbound vials at $299–$449. Try Ageless charges $159–$379 — the same band as the FDA-approved drug. You are not buying cheaper; you are buying unreviewed.
Two more findings. Its shortage justification is obsolete — FDA declared tirzepatide resolved 19 December 2024 and semaglutide 21 February 2025, with 503A deadlines passing in early 2025. And the urgency countdown is fake: two independent browser sessions both showed “Ends in 23 h 59 m 53 s”. It restarts for every visitor.
Affiliate disclosure: GLP1Drugs.org earns a commission if you buy through the links on this page — and you should know this programme pays $300 for a weight-loss signup against $160 for TRT, NAD or sermorelin. Our advice here is to price the FDA-approved drug first, which pays us nothing. Verified 8 August 2026.
Visit Try AgelessOur Top Recommended Provider: CoreAge Rx
After reviewing dozens of GLP-1 telehealth providers, CoreAge Rx is the one we recommend most. CoreAge Rx is one of our partners — read on for why we recommend them:
Flat-Rate Pricing
Same cost at every dose level — no price jumps as you titrate up.
Verified Pharmacies
US-licensed physicians and NABP-verified 503A compounding pharmacies you can trust.
Everything Included
Medication, supplies, free shipping, and ongoing clinical support — no hidden fees.
Active Community of Members
Ask questions, share progress, and get answers from other patients on the same journey — alongside ongoing clinical support from your care team.
$349
Wegovy Self-Pay, NovoCare
$1,300
The 'Retail' It Compares To
23:59
Timer, Identical In Both Sessions
$300
Its Commission To Us Vs $160
What We Verified Ourselves
Six findings — two crediting the company, four checked against outside sources or tested directly.
The Compounding Disclosure Is Genuinely Good
Repeated across several pages: 'Compounded medications, including semaglutide and tirzepatide, are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality.' Many competitors bury this. Credit where due
But The Shortage Justification Expired In 2025
The site says compounded versions may be prescribed 'such as during FDA-declared shortages'. FDA declared the tirzepatide shortage resolved on 19 December 2024 and semaglutide on 21 February 2025, with 503A deadlines passing in February and April 2025
The Savings Comparison Uses A Fictional Price
The page contrasts its plans against '~$1,300/mo' retail and '~$15,600' a year, claiming you 'SAVE ~$13,700'. NovoCare sells Wegovy self-pay at $349/month and LillyDirect sells Zepbound vials at $299-$449
So Its Own Prices Overlap The Approved Drug
Try Ageless quotes $159 to $379 a month. The FDA-approved branded products are available direct from their manufacturers in roughly the same range — meaning the trade-off is not price, it is regulatory status
The Countdown Timer Is Verifiably Fake
We loaded the page in two independent browser sessions. Both showed 'Ends in 23 h 59 m 53 s'. A real deadline would show different remaining time to different visitors. It resets to 24 hours for everyone
Free Anastrozole Is A Clinical Problem
TRT plans advertise 'Free Anastrozole'. Anastrozole is an aromatase inhibitor not FDA-approved for men; routine use to suppress oestradiol is contested and carries bone-density and lipid concerns. It should follow an indication, not a promotion
What The Approved Drugs Actually Cost Now
Get these two quotes before you sign anything. The comparison the site makes is against the third row, which the manufacturers no longer charge self-pay patients.
| Route | Monthly cash cost | FDA-approved? |
|---|---|---|
| Zepbound via LillyDirect | $299–$449 by dose | Yes |
| Wegovy via NovoCare | $349 standard doses; oral from $149 | Yes |
| Try Ageless compounded | $159–$379 depending on plan length | No — stated on its own site |
| The “retail” it compares to | ~$1,300/month, ~$15,600/year | Not what manufacturers charge self-pay |
Read the first three rows together: the approved and unapproved options overlap on price. That reframes the decision entirely — it is not thrift versus expense, it is a reviewed medicine in the manufacturer's own device versus a preparation the FDA has not assessed for potency, purity or bioequivalence. Our provider rankings compare routes including those dispensing FDA-approved product, and our side-effects guide covers what to expect either way.
Pros & Cons
Pros
- ✓Unusually thorough compounding disclosure, stated plainly and repeated: compounded semaglutide and tirzepatide 'are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality'
- ✓The site also warns that compounded products 'may differ from the branded product in formulation, inactive ingredients, or delivery device' — a real risk most sellers omit
- ✓Two clinicians are named publicly, Matthew Brooks MD and Anika Shah DO, which is more than many telehealth sites offer
- ✓TRT is gated behind actual bloodwork — you either upload recent labs or use LabCorp or Quest through the clinic
- ✓Provider consultations every three months are built into the TRT plans rather than sold as add-ons
- ✓Fertility preservation is offered alongside testosterone in the form of HCG and enclomiphene, which is clinically thoughtful and often neglected by online TRT sellers
- ✓Kyzatrex, an actually FDA-approved oral testosterone, is offered as an option rather than only compounded formulations
- ✓Unlimited clinician messaging with no additional consultation fees, and stated cancellation at any time with no contracts
- ✓503A state-licensed pharmacies are named as the dispensing channel, with cGMP standards claimed
- ✓Pricing is transparent on the page rather than hidden behind a questionnaire
Cons
- ✕The headline savings claim compares against roughly $1,300 a month, which is far above what the manufacturers' own cash programmes charge
- ✕Wegovy self-pay through NovoCare Pharmacy was $349 a month for standard doses, and Zepbound vials through LillyDirect $299-$449 — so the '~$13,700' annual saving does not survive contact with those figures
- ✕Its own $159-$379 monthly pricing sits in the same band as the FDA-approved branded drugs, so you may be paying similar money for a product with no FDA review
- ✕The stated justification of 'FDA-declared shortages' no longer applies: those shortages were declared resolved in December 2024 and February 2025
- ✕We verified the urgency countdown is fake — two independent sessions both showed the same 23 h 59 m 53 s remaining
- ✕Rotating notifications present specific outcome claims, including 'lost 14 lbs in month 1 on tirzepatide', which is an efficacy promise via testimonial
- ✕'Tirzepatide Drops' and sublingual troches are sold as needle-free options, but peptide absorption through the mouth has no established bioavailability
- ✕TRT plans advertise free anastrozole, an aromatase inhibitor not FDA-approved for men whose routine use is contested and carries bone-density risk
- ✕An FAQ actively addresses stacking GLP-1s with TRT or sermorelin, which promotes polypharmacy across three unrelated systems
- ✕Sermorelin is offered in troche, injection and nasal spray forms, though no sermorelin product is FDA-approved and marketed in the US and anti-ageing use is not an approved indication
- ✕NAD+ plans are sold despite there being no approved indication and no persuasive human efficacy evidence
- ✕We could not tie either named clinician to a specific licence, because no state or NPI is published alongside the names
- ✕The affiliate programme pays $300 for a weight-loss signup against $160 for TRT, NAD or sermorelin — a structure that rewards steering people to the most expensive category
Our Verdict
2.4 / 5 — honest about what compounding is, and dishonest about what the alternative costs.
There is real credit to give. Try Ageless states across several pages that compounded semaglutide and tirzepatide 'are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality', and adds that they may differ from the branded product in formulation, inactive ingredients or delivery device. That is the disclosure that matters and plenty of competitors bury it. It names two clinicians rather than hiding behind 'licensed providers'. Its TRT plans require actual bloodwork, build in quarterly clinician review, and include HCG and enclomiphene for fertility preservation — testosterone suppresses sperm production, and many online sellers never raise it. It offers Kyzatrex, a genuinely FDA-approved oral testosterone. Cancellation is stated as available at any time with no contracts or extra consult fees.
What pulls the score down to 2.4 is that the central commercial argument does not hold. The page prices itself against roughly $1,300 a month and about $15,600 a year, claiming a saving near $13,700. Novo Nordisk sells Wegovy to self-pay patients through NovoCare at $349 a month for standard doses, with the oral tablet from $149; Eli Lilly cut Zepbound vials through LillyDirect to $299-$449 in December 2025. Try Ageless charges $159 to $379. The approved and the unapproved therefore overlap on price, which means the saving being advertised largely does not exist and the real trade-off is regulatory status, not money. Alongside that, the site's own justification — compounding 'during FDA-declared shortages' — describes a window that closed: tirzepatide's shortage was declared resolved in December 2024 and semaglutide's in February 2025, with the 503A deadlines passing in February and April 2025.
Three further problems. We tested the urgency countdown in two independent browser sessions and both showed 23 hours, 59 minutes and 53 seconds remaining — it resets for every visitor, which is manufactured pressure applied to a prescription decision. The needle-free 'drops' and troches sell sublingual peptides, and peptide absorption across the mouth has no established bioavailability; the approved oral semaglutide needed a specific absorption enhancer to reach about 1%. And TRT plans advertise free anastrozole, an aromatase inhibitor not approved for men, whose routine use alongside testosterone is contested and carries bone-density and lipid consequences — a drug should follow an indication and a measured oestradiol, not a promotion. Our recommendation is concrete: get a quote from NovoCare and LillyDirect first. If the approved product is within reach at similar money, take it. Consider compounding only if there is a specific clinical reason the approved products cannot serve you, and ask them to name it.
Visit Try AgelessFrequently Asked Questions
Is compounded semaglutide the same as Wegovy or Ozempic?
No, and Try Ageless says so more clearly than most of its competitors, which is worth acknowledging before the criticism. Its own pages state that 'Compounded medications, including semaglutide and tirzepatide, are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality', and elsewhere that compounded products 'may differ from the branded product in formulation, inactive ingredients, or delivery device'. That is accurate and it is the disclosure that matters. What it means practically: a compounded product shares an active ingredient name with the branded drug, but the specific preparation you receive has not been through FDA review for potency, purity, stability or bioequivalence. Nobody has demonstrated that the vial you get delivers the same amount of drug into your bloodstream as a Wegovy pen. The clinical trial results everyone quotes — the mean 14.9% body-weight reduction with semaglutide 2.4mg over 68 weeks in STEP 1, or 20.9% with tirzepatide 15mg over 72 weeks in SURMOUNT-1 — were produced with the branded products, not with compounded copies, and cannot be transferred to them. Compounded medicines have a legitimate purpose: making something for an individual whose needs the approved product cannot meet. Selling copies at scale is a different activity.
Is compounding even permitted for these drugs now?
Only in narrow circumstances, and the justification the site cites is out of date. Try Ageless states that compounded versions 'may be prescribed by independent licensed physicians when clinically appropriate, such as during FDA-declared shortages or to meet specific patient needs'. The shortage half of that no longer describes reality. FDA determined the tirzepatide shortage resolved on 19 December 2024 and the semaglutide shortage resolved on 21 February 2025. It then set wind-down deadlines: 503A state-licensed pharmacies had until 19 February 2025 for tirzepatide and 22 April 2025 for semaglutide, with 503B outsourcing facilities given until 19 March and 22 May 2025 respectively. The Outsourcing Facilities Association sued over both determinations and courts declined to grant preliminary injunctions, so the deadlines held. Being on the shortage list was the primary legal basis that let 503A pharmacies compound something that is 'essentially a copy' of a commercially available branded drug, and that basis is gone. What remains lawful is compounding for a documented individual clinical need the approved product cannot meet — a genuine allergy to an inactive ingredient, say, or a dose that is not commercially made. That is a much narrower doorway than a subscription plan advertised to anyone who passes a five-minute assessment, and it is worth asking any seller which specific patient need justifies your prescription.
Are the savings claims accurate?
No, and this is the most consequential problem on the page. The weight-loss plan page sets its pricing against a retail comparison of roughly $1,300 a month, an annual cash cost of about $15,600, and a headline saving of approximately $13,700. That comparison would have been roughly fair a couple of years ago against a list price with no insurance. It is not fair now. Novo Nordisk sells Wegovy directly to self-pay patients through NovoCare Pharmacy at $349 a month for the 0.25mg through 2.4mg doses, $399 for the 7.2mg high-dose version, with introductory pricing of $199 a month for the first two months on the lowest doses, and the oral Wegovy pill from $149 a month. Eli Lilly cut Zepbound vial pricing through LillyDirect in December 2025 to $299-$449 depending on dose. So the FDA-approved branded medication, bought directly from the company that makes it, costs somewhere around $299 to $449 a month — call it $3,600 to $5,400 a year, not $15,600. Against that, a claimed saving of $13,700 is not a saving at all. Worse for the argument, Try Ageless's own prices run $159 to $379 a month, which overlaps the approved product's range. The honest framing is that you are not choosing a cheaper drug; you are choosing between a reviewed drug and an unreviewed one at broadly similar cost.
Is the countdown timer real?
No, and we tested it rather than assuming. Both the weight-loss and TRT pages display a discount with an urgency timer — '$50 OFF Your First Month, AUTOMATICALLY APPLIED, Ends in 23 h 59 m 47 s' and similar. We loaded the page in one browser session and recorded the timer, then loaded it again in a completely separate, fresh browser context with no shared cookies or storage. Both showed the same figure: 23 hours, 59 minutes and 53 seconds remaining. A genuine deadline is a fixed point in time, so two visitors arriving at different moments would see different amounts of time left. A timer that starts at almost exactly 24 hours for every new visitor is not counting down to anything; it resets on arrival. This is a manufactured scarcity cue, and it is worth naming because of what it is doing: pressing someone to make a prescription-medication decision quickly. Time pressure is inappropriate in that context in a way it would not be for a jumper. The same pages also run rotating notifications — 'Michael T. from Houston, TX lost 14 lbs in month 1 on tirzepatide', 'Brian T. from Florida just got $50 off his first month', '1,247 men took the assessment this week'. Treat those as marketing furniture too, and note the first is an efficacy claim delivered as a testimonial.
What about the sublingual drops and troches?
Be sceptical, because the absorption problem is real and unsolved. Try Ageless sells Tirzepatide Drops and Sermorelin Troches among its needle-free options, and its own FAQ asks why the drops are cheaper than the injection. The pharmacology is the issue. Semaglutide and tirzepatide are peptides — large, fragile molecules that are digested and poorly absorbed across mucous membranes. This is not a marketing objection but the reason the only approved oral semaglutide product, Rybelsus, required a specific absorption enhancer called SNAC and still achieves roughly 1% bioavailability, which is why its oral doses are many times larger than the injectable equivalents. A compounded drop or troche has no equivalent formulation science behind it and no bioequivalence data. The plausible outcomes are that you absorb very little, or that absorption varies unpredictably between doses — and with a drug titrated by response, unpredictable absorption is not a neutral property. If needles are genuinely the obstacle for you, that is a real problem worth solving, and the honest routes are the approved oral tablet, a different injection device, or help with needle anxiety. Paying less for a sublingual peptide is only a saving if it works, and nobody has shown that it does.
Should I be worried about the free anastrozole with TRT?
Yes, and it is the finding we would most want a man considering these plans to read. The TRT pages advertise anastrozole as included, in one place as 'Free Anastrozole'. Anastrozole is an aromatase inhibitor — it blocks the conversion of testosterone to oestradiol — and it is licensed for breast cancer in women, not for men. Its use in men on testosterone therapy is off-label and genuinely contested. Oestradiol in men is not a waste product: it is necessary for bone mineral density, lipid handling, libido and mood, and suppressing it too far causes joint pain, low libido, mood disturbance and, over time, bone loss. Mainstream endocrine guidance does not support routinely prescribing an aromatase inhibitor alongside testosterone; it is reserved for specific problems such as symptomatic gynaecomastia with a genuinely raised oestradiol, and it should be driven by symptoms and measured levels. Bundling it into a plan as a free inclusion inverts that: the drug arrives before the indication does. If you are prescribed anastrozole, ask what your measured oestradiol was, what symptom it is treating, and how it will be monitored. On the other side, we should credit that these plans include HCG and enclomiphene for fertility preservation — testosterone suppresses sperm production, and many online TRT sellers never mention it.
Should I stack GLP-1s with TRT and sermorelin?
We would not, and the fact that an FAQ exists to encourage it is itself informative. The page carries the question 'CAN I STACK GLP-1S WITH TRT OR SERMORELIN?', which tells you the business model involves selling more than one category to the same person. Consider each. A GLP-1 for weight management has strong trial evidence behind the branded versions. Testosterone replacement has a legitimate evidence base when there is genuine, biochemically confirmed hypogonadism — meaning low morning testosterone on at least two separate occasions with symptoms — and it requires ongoing monitoring of haematocrit, PSA where appropriate, and symptoms, because it can raise red cell mass and has fertility consequences. Sermorelin is a growth hormone releasing analogue; no sermorelin product is FDA-approved and marketed in the United States today, and using growth hormone secretagogues for anti-ageing or body composition is not an approved indication and lacks the evidence to support it. NAD+ injections have no approved indication and no persuasive human efficacy data. Stacking these means taking one well-evidenced medicine alongside two or three that are not, from one commercial supplier, with no trial data on the combination. If you have symptoms of low testosterone, get that investigated properly on its own merits — not as an add-on to a weight-loss subscription.
Who are the clinicians and can you verify them?
Two are named and we could not confirm either to a specific licence, which is a gap rather than an accusation. The medical experts page names Matthew Brooks MD and Anika Shah DO. Naming clinicians at all puts Try Ageless ahead of the many telehealth sites that reference 'licensed U.S. providers' and never say who. But verification needs more than a name. We searched the federal NPI registry: 'Matthew Brooks' returns twenty records spanning emergency medicine in Delaware and Pennsylvania, a hospitalist in Missouri, a psychologist in Washington and others, with no way to tell which is intended. 'Anika Shah' returns two, of whom one is an internal medicine physician in Pennsylvania. Neither the state, the NPI number nor the licence number is published alongside the names on the site, so the claim is not checkable. For comparison, when a brand publishes enough detail we can confirm a unique match in seconds — we did exactly that for another company this week. Two practical suggestions. Ask which licensed clinician will be responsible for your prescription and in which state they are licensed, and check that state's board yourself. And note the site's own careful wording: it 'facilitates coordination and communication with licensed healthcare providers', which describes a platform rather than a medical practice.
Who should consider this and who should not?
Consider it only after you have priced the FDA-approved alternative, because for most people that is now the better deal on identical or near-identical money. Get a quote from NovoCare Pharmacy for Wegovy and from LillyDirect for Zepbound, and compare those against Try Ageless's $159 to $379. If the approved product lands within reach, take the reviewed medicine in the manufacturer's own device with the manufacturer's own quality control. Consider Try Ageless if there is a genuine reason the approved products do not work for you — a documented allergy to an inactive ingredient, or a dose that is not commercially made — because that is what compounding legitimately exists for, and ask them to identify which specific need justifies your prescription. Do not choose it on the strength of the savings comparison, which measures against a price the manufacturers no longer charge. Do not buy the drops or troches expecting them to work like injections. Do not accept anastrozole without a measured oestradiol and a symptom to treat. And do not let a countdown timer set the pace of a decision about prescription medication — we tested it, and it restarts for every visitor. If you want a genuinely low-cost route, our provider rankings compare options including those dispensing FDA-approved product.
Get Two Quotes Before You Sign Anything
NovoCare for Wegovy, LillyDirect for Zepbound. If the FDA-approved drug lands near the compounded price — and it often does now — take the one that has been reviewed.
Visit Try AgelessCompare Other GLP-1 Providers
See how other telehealth providers stack up.
CoreAge Rx
#1 RecommendedFlat-rate pricing for compounded semaglutide and tirzepatide with NABP-verified pharmacies
Read Review →Boston Medical Group
Top RatedEstablished telehealth provider with physician oversight and transparent pricing
Read Review →Form Health
Comprehensive ProgramMultidisciplinary obesity medicine program with physicians, dietitians, and behavioral coaching
Read Review →PlushCare
Insurance AcceptedMajor telehealth platform with brand-name FDA-approved GLP-1s, insurance support, and 1M+ members treated
Read Review →LifeMD
Top RatedPublicly traded telehealth company with comprehensive health platform and competitive pricing
Read Review →GoodRx Care
Trusted BrandTelehealth platform from GoodRx with transparent pricing and established trust
Read Review →Medical Disclaimer: This page is informational and is not medical advice. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, efficacy or quality; they are not therapeutically equivalent to branded products and efficacy figures from trials of branded drugs cannot be assumed to apply to them. GLP-1 receptor agonists carry a boxed warning regarding thyroid C-cell tumours and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2; reported adverse effects include pancreatitis, gallbladder disease, severe gastrointestinal reactions and, where volume depletion occurs, acute kidney injury. They are not recommended in pregnancy, and tirzepatide labelling advises additional contraceptive precautions for users of oral hormonal contraceptives. Testosterone is a controlled substance whose appropriate use requires biochemically confirmed hypogonadism, typically low morning testosterone on at least two occasions with consistent symptoms, and ongoing monitoring including haematocrit; it suppresses spermatogenesis and impairs fertility. Anastrozole is not FDA-approved for use in men; suppressing oestradiol can adversely affect bone mineral density, lipids, libido and mood, and it should not be taken without a measured oestradiol, a clinical indication and monitoring. No sermorelin product is FDA-approved and marketed in the United States, and use of growth hormone secretagogues for anti-ageing or body composition is not an approved indication. NAD+ administration has no approved indication and no established efficacy. Sublingual and oral peptide preparations have no established bioavailability. Consult a licensed clinician who is not selling you the product before starting, combining or changing any treatment.
Date reviewed: 8 August 2026. Prices, plan structures, disclosures and site copy were read from tryageless.com on that date and may change, including weight-loss plans quoted from $159 to $379 per month with figures of $199/mo and $249/mo on specific terms, TRT plans from $129 to $209 per month on three-month terms with totals of $387 to $1,227, and a comparison table citing approximately $1,300 per month retail, an annual cash cost of about $15,600 and a saving of approximately $13,700. Quoted disclosures are the company's own wording: 'Compounded medications, including semaglutide and tirzepatide, are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality'; 'Compounded medications are prepared individually and are not themselves FDA-approved, and may differ from the branded product in formulation, inactive ingredients, or delivery device'; 'compounded versions may be prescribed by independent licensed physicians when clinically appropriate, such as during FDA-declared shortages or to meet specific patient needs'; and 'Try Ageless facilitates coordination and communication with licensed healthcare providers'. The countdown timer was tested by loading the weight-loss plan page in two separate, independent browser contexts with no shared storage; both displayed 'Ends in 23 h 59 m 53 s'. Rotating on-page notifications observed included 'lost 14 lbs in month 1 on tirzepatide' and '1,247 men took the assessment this week'. The medical experts page named Matthew Brooks MD and Anika Shah DO; a search of the CMS National Provider Identifier registry returned twenty records for the former and two for the latter, and with no state, licence or NPI published we could not confirm a unique match. Comparison pricing is as published by the manufacturers' own programmes: Wegovy self-pay through NovoCare Pharmacy at $349 per month for 0.25mg to 2.4mg doses and $399 for the 7.2mg high dose, with introductory pricing of $199 per month for the first two months on the two lowest doses and the oral Wegovy tablet from $149 per month; and Zepbound vials through LillyDirect at $299 to $449 depending on dose following a December 2025 reduction from $349 to $499. FDA determined the tirzepatide shortage resolved on 19 December 2024 and the semaglutide shortage resolved on 21 February 2025, with enforcement wind-down for 503A pharmacies to 19 February 2025 and 22 April 2025 respectively and for 503B outsourcing facilities to 19 March 2025 and 22 May 2025; litigation brought by the Outsourcing Facilities Association did not obtain preliminary injunctions. STEP 1 and SURMOUNT-1 figures are as published and relate to branded products. The Katalys offer lists commissions of $300 for weight loss, $160 for sermorelin, NAD and TRT three-month, and $100 default.
Affiliate Disclosure: This site may receive compensation from affiliate partners. This does not influence our editorial content or review ratings.